SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) July 15, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On July 15, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that the Company continues to compile the
data collected from the in-home study of the Diasensorr1000
noninvasive glucose sensor for diabetics. Once the data is
compiled, it will then be inserted in a 510(k) Notification for
resubmission to the Food and Drug Administration (FDA).
The Company further stated that at the Beijing Medical Show
held in China June 25 - 29 and at private seminars held for
physicians afterward in Beijing and Shanghai, the Diasensor 1000
was greeted with much enthusiasm. Biocontrol is moving forward to
market the Diasensor 1000 in Hong Kong, Shanghai, and Beijing,
China through BICO's recently formed joint venture, Superpower-
BICO International Group, Inc. (SBIG).
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: July 15, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone 1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL COMPILING DATA FROM IN-HOME STUDY ON DIASENSORr1000
Pittsburgh, PA - July 15, 1997 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that the Company continues to
compile the data collected from the in-home study of the
Diasensorr1000 noninvasive glucose sensor for diabetics. Once
the data is compiled, it will then be inserted in a 510(k)
Notification for resubmission to the Food and Drug Administration
(FDA).
While compiling the data, the Company continues to test the
sensor with additional in-home patients. All calibrations of the
device are being done in the home, rather than in a testing
center, as recent tests have shown this produces better results
by reducing the effect on the Diasensor 1000 of variables such as
temperature, barometric pressure, and humidity.
Using near-infrared technology, the Diasensor 1000 measures
glucose levels in the blood without the need to finger prick.
The Company further stated that at the Beijing Medical Show
held in China June 25 - 29 and at private seminars held for
physicians afterward in Beijing and Shanghai, the Diasensor 1000
was greeted with much enthusiasm. Biocontrol is moving forward to
market the Diasensor 1000 in Hong Kong, Shanghai, and Beijing,
China through BICO's recently formed joint venture, Superpower-
BICO International Group, Inc. (SBIG).
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products.
